Safety question

Is Atomoxetine (Strattera) safe?

Generally yes, with attention to dose and timing. Atomoxetine (Strattera) scores 4/5. Adverse reactions are uncommon, minor, and reversible on stopping. The main risks are dose-related — starting at the low end of the clinical range and titrating up gives the best safety margin.

Common side effects

• Insomniamoderate
• Decreased appetitemoderate

Rare side effects

• Liver injury (rare)severe

Who should not take Atomoxetine (Strattera)

• Pregnant or breastfeeding individuals — most nootropics have not been adequately studied in pregnancy, and the precautionary principle applies.
• Anyone on a prescription medication that overlaps mechanistically (stimulants, SSRIs, MAOIs, beta-blockers, anticoagulants) — clear interactions with your prescribing clinician before adding Atomoxetine (Strattera).
• Anyone with significant cardiovascular, hepatic, renal, or psychiatric disease — established conditions raise the baseline risk for any new compound.
• Minors — almost no nootropics have a paediatric safety record, and developing brains are differently sensitive.

What "safe" means here

Our safety scoring reflects (a) published clinical and observational literature on healthy-adult use at standard supplement doses, (b) the spectrum of adverse-event reports in the medical and supplement-pharmacovigilance record, and (c) the regulatory status across major jurisdictions. It does notreflect long-term outcomes in populations that haven’t been studied, and it does not substitute for clinical judgement applied to your individual situation.

A 5/5 score does not mean “no risk” — it means risk has been quantified as low in healthy adults at usual doses. Idiosyncratic and allergic reactions are possible with virtually any compound, including those we rate highest.

This page is informational. It is not medical advice and does not establish a clinician-patient relationship. Individual risk varies with genetics, medications, pre-existing conditions, and dose. Always consult a qualified clinician before starting a new compound. See our full disclaimer and terms.